Treatment with epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs)
improves the overall survival of patients with EGFR-mutated non-small-cell lung cancer …

Almost 17% of Western patients affected by non-small cell lung cancer (NSCLC) have an
activating epidermal growth factor receptor (EGFR) gene mutation. Del19 and L858R are the …

Recent advances in diagnosis and treatment are enabling a more targeted approach to
treating lung cancers. Therapy targeting the specific oncogenic driver mutation could inhibit …

Simple Summary Non-small cell lung cancer (NSCLC) is the most common cancer in the
world. For common EGFR mutations, treatment is based on different inhibitors. Despite the …

Mutations in the epidermal growth factor receptor (EGFR) gene are the most common
targetable genomic drivers of non-small cell lung cancer (NSCLC), occurring in …

The discovery that mutations in the EGFR gene are detected in up to 50% of lung
adenocarcinoma patients, along with the development of highly efficacious epidermal …

Activating mutations of the epidermal growth factor receptor gene (EGFR) are a driving force
for some lung adenocarcinomas. Several randomized phase III studies have revealed that …

Tyrosine kinase inhibitors (TKIs) are the standard of care for patients with non-small cell lung
cancer (NSCLC) that harbor mutations of the epidermal growth factor receptor (EGFR) gene …

Epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) represents a paradigm
shift in the treatment of non-small cell lung cancer (NSCLC) patients and has been the first …

First-and second-generation epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (TKIs) are the evidence-based first-line treatment for metastatic non-small-cell lung …